EBITDA Margin (Quarterly)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

Neurocrine Biosciences, Inc. (NBIX) EBITDA Margin data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$794.90M
Net Income	$209.50M
Cost of Goods Sold	$14.00M
Gross Profit	$780.90M
Operating Expenses	$555.90M
Operating Income	$239.00M
Non-Operating Income/Expense	$52.80M
Pre-Tax Income	$291.80M
Normalized Pre-Tax Income	$261.20M
Income after Taxes	$209.50M
Income from Continuous Operations	$209.50M
Consolidated Net Income/Loss	$209.50M
Normalized Income after Taxes	$170.27M
EBIT	$239.00M
EBITDA	$246.70M
Weighted-Average Shares Outstanding (Basic)	99.40M
Weighted-Average Shares Outstanding (Diluted)	102.50M
Earnings per Share (EPS) (Basic)	$2.11
Earnings per Share (EPS) (Diluted)	$2.04
Balance Sheet Financials
Current Assets	$2.16B
Property, Plant, and Equipment	$97.30M
Long-Term Assets	$2.11B
Total Assets	$4.27B
Current Liabilities	$638.00M
Long-Term Debt	--
Long-Term Liabilities	$624.10M
Total Liabilities	$1.26B
Common Equity	$3.00B
Tangible Shareholders Equity	$2.97B
Shareholders Equity	$3.00B
Common Shares Outstanding	99.70M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$394.30M
Cash Flow from Investing Activities	$-211.50M
Cash Flow from Financial Activities	$-75.60M
Beginning Cash	$241.00M
End Cash	$348.20M
Increase/Decrease in Cash	$107.20M
Stock-Based Compensation	$159.30M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.38
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	98.24%
Operating Margin	30.07%
EBIT Margin	30.07%
EBITDA Margin	--
Pre-Tax Profit Margin	36.71%
Profit Margin	26.36%
Free Cash Flow	$357.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.19
Inventory Turnover	0.20
Receiveable Turnover	1.09
Days Sales in Receivables	82.43
Return on Equity	6.97%
Return on Tangible Equity	7.06%
Return on Assets	4.91%
Return on Investments	6.97%
Book Value Per Share	$30.13
Free Cash Flow per Share	$3.49
Operating Cash Flow per Share	$3.85

Data from Zacks Investment Research, Inc.